Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Dong, Zhong-Yi, Zhong, Wen-Zhao, Zhang, Xu-Chao, Su, Jian, Xie, Zhi, Liu, Si-Yang, Tu, Hai-Yan, Chen, Hua-Jun +11 more·2017·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-16-2554

Cited by (983)

Items 901–983 of 983

  1. Additional file 2 of Genomic features and its potential implication in bone oligometastatic NSCLC
    Rongxin Liao, Guangming Yi, Lu Shen, Zhang, Xiaoyue, Zaicheng Xu, Yuan Peng, Yang, Zhenzhou · 2023 · Figshare
  2. Additional file 1 of Establishment and validation of an immune infiltration predictive model for ovarian cancer
    Zhenxia Song, Zhang, Jingwen, Yue Sun, Jiang, Zhongmin, Liu, Xiaoning · 2023 · Figshare
  3. Additional file 8 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
  4. Additional file 1 of Determining the prognosis of Lung cancer from mutated genes using a deep learning survival model: a large multi-center study
    Peng, Jie, Xiao, Lushan, Zhu, Hongbo, Han, Lijie, Honglian Ma · 2024 · Figshare
  5. Additional file 1 of Exploring immunotherapy in colorectal cancer
    Weng, Junyong, Shanbao Li, Zhu, Zhonglin, Liu, Qi, Ruoxin Zhang, Yang, Yufei, Li, Xinxiang · 2022 · Figshare
  6. Additional file 1 of Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers
    Zhang, Peng, Huang, Yixuan · 2021 · Figshare
  7. Additional file 4 of A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma
    Shi, Congyu, Liu, Shan, Tian, Xudong, Wang, Xiaoyi, Gao, Pan · 2021 · Figshare
  8. Additional file 1 of A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
    Peiling Xie, An, Rui, Yu, Shibo, He, Jianjun, Zhang, Huimin · 2021 · Figshare
  9. Additional file 10 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
  10. Additional file 1 of Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC
    Sun, Yiting, Duan, Jianchun, Fang, Wenfeng, Wang, Zhijie, Du, Xinyang, Wang, Xin, Chengcheng Li, Cai, Shangli, Zhao, Jie, Li, Sini et al. · 2021 · Figshare
  11. Additional file 3 of Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma
    Li, Shuyang, Wei Wang, Huihan Yu, Zhang, Siyu, Wenxu Bi, Suling Sun, Hong, Bo, Zhiyou Fang, Chen, Xueran · 2024 · Figshare
  12. Additional file 6 of Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma
    Li, Shuyang, Wang, Wei, Huihan Yu, Zhang, Siyu, Wenxu Bi, Suling Sun, Hong, Bo, Zhiyou Fang, Chen, Xueran · 2024 · Figshare
  13. Additional file 9 of A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma
    Shi, Congyu, Liu, Shan, Tian, Xudong, Wang, Xiaoyi, Gao, Pan · 2021 · Figshare
  14. Additional file 1 of Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice
    Song, Mengqi, Cheng, Haoyue, Zou, Hao, Ma, Kai, Lu, Lianfang, Qian Wei, Zejiang Xu, Tang, Zirui, Zhang, Yuanzheng, Wang, Yinan et al. · 2024 · Figshare
  15. Additional file 4 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
  16. Additional file 2 of Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice
    Song, Mengqi, Cheng, Haoyue, Zou, Hao, Ma, Kai, Lu, Lianfang, Qian Wei, Zejiang Xu, Tang, Zirui, Zhang, Yuanzheng, Wang, Yinan et al. · 2024 · Figshare
  17. Additional file 12 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
  18. Additional file 5 of A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma
    Shi, Congyu, Liu, Shan, Tian, Xudong, Wang, Xiaoyi, Gao, Pan · 2021 · Figshare
  19. Additional file 3 of Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma
    Zhang, Jin, Yan, Aiting, Cao, Wei, Shi, Honglei, Cao, Kai, Liu, Xiaowu · 2020 · Figshare
  20. Additional file 3 of Eleven immune-gene pairs signature associated with TP53 predicting the overall survival of gastric cancer: a retrospective analysis of large sample and multicenter from public database
    Huo, Junyu, Liqun Wu, Zang, Yunjin · 2021 · Figshare
  21. Additional file 4 of Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
    He Li, Lei Yang, Wang, Yuanyuan, Lingchan Wang, Chen, Gang, Li Zhang, Wang, Dongchang · 2023 · Figshare
  22. Additional file 5 of Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma
    Li, Shuyang, Wei Wang, Huihan Yu, Zhang, Siyu, Wenxu Bi, Suling Sun, Hong, Bo, Zhiyou Fang, Chen, Xueran · 2024 · Figshare
  23. Additional file 7 of A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma
    Shi, Congyu, Liu, Shan, Tian, Xudong, Wang, Xiaoyi, Gao, Pan · 2021 · Figshare
  24. Additional file 6 of The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity
    Ge, You, Feiran Wei, Guoping Du, Fei, Gaoqiang, Wei Li, Li, Xiaoshan, Chu, Jinjin, Wei, Pingmin · 2021 · Figshare
  25. Additional file 1 of The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity
    Ge, You, Feiran Wei, Guoping Du, Fei, Gaoqiang, Wei Li, Li, Xiaoshan, Chu, Jinjin, Wei, Pingmin · 2021 · Figshare
  26. Additional file 7 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
  27. Additional file 3 of Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
    He Li, Lei Yang, Wang, Yuanyuan, Lingchan Wang, Chen, Gang, Li Zhang, Wang, Dongchang · 2023 · Figshare
  28. Additional file 4 of Establishment and validation of an immune infiltration predictive model for ovarian cancer
    Zhenxia Song, Zhang, Jingwen, Sun, Yue, Jiang, Zhongmin, Liu, Xiaoning · 2023 · Figshare
  29. Additional file 2 of Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers
    Zhang, Peng, Huang, Yixuan · 2021 · Figshare
  30. Additional file 15 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
  31. Additional file 4 of Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma
    Li, Shuyang, Wei Wang, Huihan Yu, Zhang, Siyu, Wenxu Bi, Suling Sun, Hong, Bo, Zhiyou Fang, Chen, Xueran · 2024 · Figshare
  32. Additional file 2 of Establishment and validation of an immune infiltration predictive model for ovarian cancer
    Zhenxia Song, Zhang, Jingwen, Yue Sun, Jiang, Zhongmin, Liu, Xiaoning · 2023 · Figshare
  33. Additional file 5 of Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma
    Zhang, Jin, Yan, Aiting, Cao, Wei, Shi, Honglei, Cao, Kai, Liu, Xiaowu · 2020 · Figshare
  34. Additional file 11 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
  35. Additional file 3 of Establishment and validation of an immune infiltration predictive model for ovarian cancer
    Zhenxia Song, Zhang, Jingwen, Yue Sun, Jiang, Zhongmin, Liu, Xiaoning · 2023 · Figshare
  36. Additional file 6 of A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma
    Shi, Congyu, Liu, Shan, Tian, Xudong, Wang, Xiaoyi, Gao, Pan · 2021 · Figshare
  37. Additional file 3 of Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers
    Zhang, Peng, Huang, Yixuan · 2021 · Figshare
  38. The Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitor in ≥3 line MSS Metastatic Colorectal Cancer Patients
    Xiangyi Wang, Li Lin, jun liang · 2021 · Research Square
  39. Additional file 5 of The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity
    Ge, You, Feiran Wei, Guoping Du, Fei, Gaoqiang, Wei Li, Li, Xiaoshan, Chu, Jinjin, Wei, Pingmin · 2021 · Figshare
  40. Additional file 1 of A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma
    Shi, Congyu, Liu, Shan, Tian, Xudong, Wang, Xiaoyi, Gao, Pan · 2021 · Figshare
  41. Additional file 1 of Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
    He Li, Lei Yang, Wang, Yuanyuan, Lingchan Wang, Chen, Gang, Li Zhang, Wang, Dongchang · 2023 · Figshare
  42. Additional file 6 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
  43. Additional file 1 of Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer
    Xiaoqing Luo, Peng, Shunli, Sijie Ding, Zeng, Qin, Wang, Rong, Ma, Yueyun, Chen, ShiYu, Wang, Yanxia, Wang, Wei · 2021 · Figshare
  44. Additional file 2 of A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma
    Shi, Congyu, Liu, Shan, Tian, Xudong, Wang, Xiaoyi, Gao, Pan · 2021 · Figshare
  45. Additional file 5 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
  46. Additional file 4 of Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma
    Zhang, Jin, Yan, Aiting, Cao, Wei, Shi, Honglei, Cao, Kai, Liu, Xiaowu · 2020 · Figshare
  47. Additional file 2 of Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma
    Zhang, Jin, Yan, Aiting, Cao, Wei, Shi, Honglei, Cao, Kai, Liu, Xiaowu · 2020 · Figshare
  48. Additional file 1 of Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation
    Dejun Zeng, Zhengyang Hu, Yanjun Yi, Valeria, Besskaya, Guangyao Shan, Chen, Zhencong, Zhan, Cheng, Miao Lin, Lin, Zongwu, Qun Wang · 2021 · Figshare
  49. Additional file 2 of Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma
    Li, Shuyang, Wang, Wei, Huihan Yu, Zhang, Siyu, Wenxu Bi, Suling Sun, Hong, Bo, Zhiyou Fang, Chen, Xueran · 2024 · Figshare
  50. Additional file 3 of The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity
    Ge, You, Feiran Wei, Guoping Du, Fei, Gaoqiang, Wei Li, Li, Xiaoshan, Chu, Jinjin, Wei, Pingmin · 2021 · Figshare
  51. Additional file 14 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
  52. Additional file 8 of A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma
    Shi, Congyu, Liu, Shan, Tian, Xudong, Wang, Xiaoyi, Gao, Pan · 2021 · Figshare
  53. Additional file 2 of Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC
    Sun, Yiting, Duan, Jianchun, Fang, Wenfeng, Wang, Zhijie, Du, Xinyang, Wang, Xin, Chengcheng Li, Cai, Shangli, Zhao, Jie, Li, Sini et al. · 2021 · Figshare
  54. Additional file 4 of The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity
    Ge, You, Feiran Wei, Guoping Du, Fei, Gaoqiang, Wei Li, Li, Xiaoshan, Chu, Jinjin, Wei, Pingmin · 2021 · Figshare
  55. Additional file 3 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Guangqiang Zhao, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
  56. A Novel Eight-lncRNA Disulfidptosis Signature Stratifies Prognosis and Immunotherapeutic Benefit in LUAD
    Thandeka Moyo, Sipho Dlamini, Kabelo Ndlovu · 2024 · Specialty journal of Pharmacognosy Phytochemistry and Biotechnology
  57. Spectrum of KRAS variants in primary lung mucinous adenocarcinoma: implications for diagnosis, testing, and therapy
    Arkar Htoo, Renuka Malenie, Juan Xing · 2026 · Journal of the American Society of Cytopathology
  58. Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer
    Koichi Azuma, Mitsuo Osuga, Shoichi Itoh, Yoshitaka Kawa, Toshiyuki Kozuki, Yukihiro Toi, Kenta Murotani, Motohiro Izumi, Daiki Murata, Akito Hata et al. · 2026 · Cancer Treatment and Research Communications
  59. Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer
    Jian Zhang, Y. Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Ying Liu, Zhen Hu · 2026 · MedComm
  60. Ultra-rare TP53 and KRAS variants predict survival in ICI-treated solid tumours
    Vicente Javier Clemente‐Suárez, Rodrigo Olivares, Rodrigo Yáñez-Sepúlveda, Eduardo Guzmán-Muñóz, Alexandra Martín Rodríguez · 2026 · Clinical & Translational Oncology
  61. Control of antitumor immunity by the SQSTM1 dependent signaling
    Nathalie Yazbeck · 2018
  62. Effet de l’inactivation du gène suppresseur de tumeur p53 et de sa réactivation pharmacologique sur la réponse cytotoxique anti-tumorale
    Marie Chollat-Namy · 2020
  63. KRAS inhibitors plus immunotherapy: Navigating efficacy, toxicity, and biomarkers
    Hiromichi Ebi · 2026 · Journal of Thoracic Oncology
  64. Targetable driver gene–tumor immune microenvironment axis in non-small cell lung cancer: from molecular pathological mechanisms to precision immunotherapy stratification strategies
    Wenqing Chen, Fengyan Zhang, Xin Zheng · 2026 · Frontiers in Immunology
  65. The p53/Mdm2 Pathway in Hepatocellular Carcinoma: From Molecular Pathogenesis to Targeted Therapies
    Keara Kirkness, Derek A. Mann · 2026 · Livers
  66. The evolving role of TP53 mutation in hepatocellular carcinoma (HCC)
    Md Rafee Ur Rahman, Xin Chen, Ananya Podder, Ximing Xu · 2026 · Cancer Cell International
  67. Distinct spatial immune microenvironment features of different EGFR mutation subtypes in early-stage lung adenocarcinoma
    Kongxu Dai, Sida Cheng, Cong Wu, Yulong Wang, Xu Liu, Xinrui Li, Yaxing Zhao, Jianpeng Sheng, Yun Li, Fan Yang et al. · 2026 · Lung Cancer
  68. mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment
    Priyatosh Nath, Alok R. Khandelwal, Chun Li, Tara Moore‐Medlin, Srivatsa Surya Vasudevan, Victor Albornoz Alvarez, Omar E. Franco, Jorge Silvio Gutkind, Cherie‐Ann O. Nathan · 2026 · Neoplasia
  69. Oncogenic KRAS in Cancer Immunotherapy: From Oncogenic Signaling to Tumor-Immune Ecosystem Regulation
    Milad Ashrafizadeh, Noushin Nabavi, Yifei Xu · 2026 · Cancer Biome and Targeted Therapy
  70. PanoraOnc: A pan-cancer clinico-genomic AI model for transferable outcome predictions
    Manuel Schuerch, Jacob Geisberg, Cameron T. Flower, Ayyüce Begüm Bektaş, Thomas O. McDonald, Satyakam Mishra, Christopher J. Graser, Jennifer Altreuter, Guruprasad Ananda, Genevieve Marie Boland et al. · 2026 · medRxiv
  71. Predicting early EGFR-TKI treatment response in EGFR-mutant lung adenocarcinoma from H&E histopathology with weakly supervised multiple-instance learning
    Weiwei Wang, Peng Zhao, Yan Zhang · 2026 · Pathology - Research and Practice
  72. Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy
    Sourio Chakraborty, Sumon Mukherjee, Subhajit Ghosh, Udit Basak, Sumoyee Mukherjee, Arghya Adhikary, Gaurisankar Sa, Tanya Das · 2026 · APOPTOSIS
  73. Spatially-resolved pharmaco-ecology of immunotherapy resistance in lung adenocarcinoma: Single-cell and spatial transcriptomics for mechanism-matched combination therapies
    Yiming Hua, Zhanyang Luo, Zhimei Huang · 2026 · Translational Oncology
  74. The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective
    Barliz Waissengrin, Marco Tagliamento, K. Nathan Sankar, Karen L. Reckamp · 2026 · Journal of Thoracic Oncology
  75. Real-World Treatment Patterns and Clinical Outcomes After First-Line Therapy in Patients with KRAS G12C-Mutant Advanced Non-Small-Cell Lung Cancer in the United States
    Kristin M. Sheffield, Tarun Puri, Kelli Thoele, Himanshu Karu, A. Mansharamani, Dipesh Uprety · 2026 · Cancers
  76. Oncogene Driver Status Modulates TP53 Prognostic Impact in Advanced NSCLC
    Minggui Pan, Chen Jiang, Janet Song, Shreyas Kudrimoti, Jacqueline V. Aredo, Heather A. Wakelee, Joel W. Neal, Jenny Zhao, Yasmine Kamgarhaghighi, Ninah S. Achacoso et al. · 2026 · medRxiv
  77. p53 Co-mutations in EGFR-mutant NSCLC: biological insight and therapeutic implications
    Julian David Etessami, Ilaria Attili, Pamela Trillo Aliaga, Matteo Cavallone, Elisa Giordano, Valerio Maria Napoli, Ester Del Signore, Gianluca Spitaleri, Giuseppe Curigliano, Antonio Passaro · 2026 · Cancer Treatment Reviews
  78. Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1
    Xin Zhang, Qian Hao, Wenyue Yang, Yunbo Yu, Qingya Yan, Zhenhua Wu, Zhihuang Hu, Xiang Yu Zhou, Jialei Wang · 2026 · Science Advances
  79. Clinical features and multidimensional prognostic model of EGFR-TKI acquired resistance in NSCLC patients with or without brain metastases
    Yuting Wang, Xia Li, Zhifang Mao, Qinglin Shen · 2026 · Cancer Treatment and Research Communications
  80. SERPINE1 promotes CRC cell invasion and metastasis through resistance to anoikis
    Yaru Zhu, Diya Liu, Zhen Ren, Hong Yuan, Linying Lai, Cheng Guo · 2026 · Molecular and Cellular Biochemistry
  81. Germline TP53 Polymorphism and Its Interaction With Somatic TP53 Mutations Shapes Response to Immune Checkpoint Inhibitors in Nonsmall Cell Lung Cancer: The Role of TP53 p.R72P as a Germline Biomarker
    Selin Kurt, Kritika Krishnamurthy · 2026 · Pathology International
  82. Clinical Utility of Broad-Panel Profiling in Non-Small Cell Lung Cancer: Pairwise Co-Mutational Gene Patterns and PD-L1 Associations Define Stage-Specific Prognosis
    Carolina Sassorossi, Elisa De Paolis, Jessica Evangelista, Davide Dalfovo, Alessandra Cancellieri, Ilenia Carriero, Annalisa Campanella, Esther G.C. Troost, Steffen Löck, Róza Ádány et al. · 2026 · Genes
  83. Uncovering KRAS -mutant allele-specific biology and vulnerabilities in non-small cell lung cancer
    Paolo D. d’Arienzo, William J. McDaid, Kirsten L. Tinsley, Tong Chen, Emma J. Gasson, Colin R. Lindsay, Angeliki Malliri · 2026 · Biochemical Journal